Clinical Risk Factors for Cutaneous Squamous Cell Carcinoma in Patients with Actinic Keratosis or Cutaneous Squamous Cell Carcinoma in Situ: A Retrospective Double-cohort Study
DOI:
https://doi.org/10.2340/actadv.v104.40990Keywords:
actinic keratosis, cancer, cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma in situ, keratinocyte carcinomaAbstract
Actinic keratosis and cutaneous squamous cell carcinoma in situ are precancerous forms of cutaneous squamous cell carcinoma. In this single-centre retrospective study, patients with histopathologically confirmed actinic keratosis (n = 121) or cutaneous squamous cell carcinoma in situ (n = 99) as their initial keratinocyte-derived lesion were compared and evaluated with regard to development of cutaneous squamous cell carcinoma during a 5-year observation period. Patients with severely dysplastic actinic keratosis or cutaneous squamous cell carcinoma in situ as their initial lesion developed cutaneous squamous cell carcinoma more rapidly than patients with actinic keratosis with mild or moderate dysplasia. With either actinic keratosis or cutaneous squamous cell carcinoma in situ as an initial lesion, advanced age, male sex, comorbidity with basal cell carcinoma, and immunosuppressive medication were associated with elevated risk of cutaneous squamous cell carcinoma development. Regarding solely patient with actinic keratosis as their initial lesion male sex, advanced age, immunosuppressive medication, location of the initial lesion, and degree of dysplasia were associated with the risk of cutaneous squamous cell carcinoma. Among patients with cutaneous squamous cell carcinoma in situ as their initial lesion, only aspirin usage was associated with increased risk of cutaneous squamous cell carcinoma. This study indicates that, among the vast and increasing population of patients with cutaneous squamous cell carcinoma precursors, male patients with immunosuppressive medication who develop basal cell carcinoma should be regarded as at heightened risk of cutaneous squamous cell carcinoma development and warrant closer surveillance.
Downloads
References
Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin N Am 2019; 33: 1-12.
https://doi.org/10.1016/j.hoc.2018.08.001 DOI: https://doi.org/10.1016/j.hoc.2018.08.001
Nehal KS, Bichakjian CK. Update on Keratinocyte Carcinomas. N Engl J Med 2018; 379: 363-374.
https://doi.org/10.1056/NEJMra1708701 DOI: https://doi.org/10.1056/NEJMra1708701
Knuutila JS, Riihilä P, Kurki S, Nissinen L, Kähäri V-M. Risk factors and prognosis for metastatic cutaneous squamous cell carcinoma: A cohort study. Acta Derm Venereol 2020; 100: adv002666.
https://doi.org/10.2340/00015555-3628 DOI: https://doi.org/10.2340/00015555-3628
Caudill J, Thomas JE, Burkhart CG. The risk of metastases from squamous cell carcinoma of the skin. Int J Dermatol 2023; 62: 483-486.
https://doi.org/10.1111/ijd.16164 DOI: https://doi.org/10.1111/ijd.16164
Fania L, Didona D, Di Pietro FR, Verkhovskaia S, Morese R, Paolino G, et al. Cutaneous squamous cell carcinoma: From pathophysiology to novel therapeutic approaches. Biomedicines 2021; 9:171.
https://doi.org/10.3390/biomedicines9020171 DOI: https://doi.org/10.3390/biomedicines9020171
Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
https://doi.org/10.1111/j.1365-2133.2005.07121.x DOI: https://doi.org/10.1111/j.1365-2133.2005.07121.x
Kandolf L, Peris K, Malvehy J, Mosterd K, Heppt MV, Fargnoli MC et al. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes). J Eur Acad Dermatol Venereol 2024; jdv.19897.
https://doi.org/10.1111/jdv.19897 DOI: https://doi.org/10.1111/jdv.19897
Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1308-1312.
https://doi.org/10.1038/bjc.1996.535 DOI: https://doi.org/10.1038/bjc.1996.535
Landis ET, Davis SA, Taheri A, Feldman SR. Top dermatologic diagnoses by age. Dermatol Online J 2014; 20: 22368.
https://doi.org/10.5070/D3204022368 DOI: https://doi.org/10.5070/D3204022368
Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-1159.
https://doi.org/10.1046/j.1365-2133.2000.03541.x DOI: https://doi.org/10.1046/j.1365-2133.2000.03541.x
Frost C, Green A, Williams G. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033-1039.
https://doi.org/10.1046/j.1365-2133.1998.02560.x DOI: https://doi.org/10.1046/j.1365-2133.1998.02560.x
Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol 2020; 83: 709-717.
https://doi.org/10.1016/j.jaad.2020.03.126 DOI: https://doi.org/10.1016/j.jaad.2020.03.126
Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156: 8-12.
https://doi.org/10.1111/j.1365-2133.2007.07860.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07860.x
Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502-518.
https://doi.org/10.1111/bjd.12420 DOI: https://doi.org/10.1111/bjd.12420
Parekh V, Seykora JT. Cutaneous squamous cell carcinoma. Clin Lab Med 2017; 37: 503-525.
https://doi.org/10.1016/j.cll.2017.06.003 DOI: https://doi.org/10.1016/j.cll.2017.06.003
Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003; 139: 66-70.
https://doi.org/10.1001/archderm.139.1.66 DOI: https://doi.org/10.1001/archderm.139.1.66
Majores M, Bierhoff E. Aktinische keratose, Morbus Bowen, keratoakanthom und plattenepithelkarzinom der haut. Pathologe 2015; 36: 16-29.
https://doi.org/10.1007/s00292-014-2063-3 DOI: https://doi.org/10.1007/s00292-014-2063-3
Fernández-Figueras MT, Carrato C, Sáenz X, Puig L, Musulen E, Ferrándiz C et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29: 991- 997.
https://doi.org/10.1111/jdv.12848 DOI: https://doi.org/10.1111/jdv.12848
Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun 2018; 9: 3667.
https://doi.org/10.1038/s41467-018-06027-1 DOI: https://doi.org/10.1038/s41467-018-06027-1
Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res 2016; 365: 691-702.
https://doi.org/10.1007/s00441-016-2457-z DOI: https://doi.org/10.1007/s00441-016-2457-z
Madani S, Marwaha S, Dusendang JR, Alexeeff S, Pham N, Chen EH et al. Ten-year follow-up of persons with sun-damaged skin associated with subsequent development of cutaneous squamous cell carcinoma. JAMA Dermatol. 2021; 157: 559-565.
https://doi.org/10.1001/jamadermatol.2021.0372 DOI: https://doi.org/10.1001/jamadermatol.2021.0372
Flohil SC, Van Der Leest RJ, Dowlatshahi EA, Hofman A, De Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol 2013;133:1971-1978.
https://doi.org/10.1038/jid.2013.134 DOI: https://doi.org/10.1038/jid.2013.134
Harwood CA, Arron ST, Proby CM, Asgari MM, Bouwes Bavinck JN, Green AC, et al. Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppression-associated keratinocyte carcinoma. Br J Dermatol 2017; 177: 1150-1151.
https://doi.org/10.1111/bjd.15932 DOI: https://doi.org/10.1111/bjd.15932
Guorgis G, Anderson CD, Lyth J, Falk M. Actinic keratosis diagnosis and increased risk of developing skin cancer: a 10-year cohort study of 17,651 patients in Sweden. Acta Derm Venereol 2020; 100: adv00128.
https://doi.org/10.2340/00015555-3486 DOI: https://doi.org/10.2340/00015555-3486
Nochaiwong S, Chuamanochan M, Ruengorn C, Noppakun K, Awiphan R, Phosuya C et al. Use of thiazide diuretics and risk of all types of skin cancers: an updated systematic review and meta-analysis. Cancers (Basel) 2022; 14: 2566.
https://doi.org/10.3390/cancers14102566 DOI: https://doi.org/10.3390/cancers14102566
Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. Cancer 2009; 115: 2523-2530.
https://doi.org/10.1002/cncr.24284 DOI: https://doi.org/10.1002/cncr.24284
Eimpunth S, Goldenberg A, Hamman MS, Oganesyan G, Lee RA, Hunnangkul S et al. Squamous cell carcinoma in situ upstaged to invasive squamous cell carcinoma: a 5-year, single institution retrospective review. Dermatol Surg 2017; 43: 698-703.
https://doi.org/10.1097/DSS.0000000000001028 DOI: https://doi.org/10.1097/DSS.0000000000001028
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23-24.
https://doi.org/10.1067/mjd.2000.103339 DOI: https://doi.org/10.1067/mjd.2000.103339
Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease). Br J Dermatol 2014; 170: 245-260.
https://doi.org/10.1111/bjd.12766 DOI: https://doi.org/10.1111/bjd.12766
Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16: 335-339.
Sober AJ, Burstein JM. Precursors to skin cancer. Cancer 1995; 75: 645-650. DOI: https://doi.org/10.1002/1097-0142(19950115)75:2+<645::AID-CNCR2820751405>3.0.CO;2-1
https://doi.org/10.1002/1097-0142(19950115)75:2+<645::AID-CNCR2820751405>3.0.CO;2-1
Zou DD, Sun YZ, Li XJ, Wu WJ, Xu D, He YT, et al. Single-cell sequencing highlights heterogeneity and malignant progression in actinic keratosis and cutaneous squamous cell carcinoma. Elife 2023; 12: e85270.
https://doi.org/10.7554/eLife.85270 DOI: https://doi.org/10.7554/eLife.85270
Fernández-Guarino M, Zamorano León JJ, López Farré AJ, González Morales ML, Sánchez Adrada AI, Barrio Garde J et al. Cytoplasmic Increase in Hsp70 Protein: A potential new biomarker of early infiltration of cutaneous squamous cell carcinoma arising from actinic keratosis. Cancers (Basel). 2020;12: 1151.
https://doi.org/10.3390/cancers12051151 DOI: https://doi.org/10.3390/cancers12051151
Knuutila JS, Riihilä P, Nissinen L, Heiskanen L, Kallionpää RE, Pellinen T, et al. Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma. Int J Cancer 2024; 155: 1112-1127.
https://doi.org/10.1002/ijc.34957 DOI: https://doi.org/10.1002/ijc.34957
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015; 348: 880-886.
https://doi.org/10.1126/science.aaa6806 DOI: https://doi.org/10.1126/science.aaa6806
Kim YS, Shin S, Jung SH, Park YM, Park GS, Lee SH et al. Genomic progression of precancerous actinic keratosis to squamous cell carcinoma. J Invest Dermatol 2022; 142: 528-538.
https://doi.org/10.1016/j.jid.2021.07.172 DOI: https://doi.org/10.1016/j.jid.2021.07.172
Karppinen SM, Honkanen HK, Heljasvaara R, Riihilä P, Autio-Harmainen H, Sormunen R, et al. Collagens XV and XVIII show different expression and localisation in cutaneous squamous cell carcinoma: type XV appears in tumor stroma, while XVIII becomes upregulated in tumor cells and lost from microvessels. Exp Dermatol. 2016; 25: 348-354.
https://doi.org/10.1111/exd.12913 DOI: https://doi.org/10.1111/exd.12913
Thomson J, Bewicke-Copley F, Anene CA, Gulati A, Nagano A, Purdie K, et al. The genomic landscape of actinic keratosis. J Invest Dermatol 2021; 141: 1664-1674.
https://doi.org/10.1016/j.jid.2020.12.024 DOI: https://doi.org/10.1016/j.jid.2020.12.024
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344; 975-983.
https://doi.org/10.1056/NEJM200103293441306 DOI: https://doi.org/10.1056/NEJM200103293441306
Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal antiinflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol 2015; 135: 975-983.
https://doi.org/10.1038/jid.2014.531 DOI: https://doi.org/10.1038/jid.2014.531
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Jaakko S. Knuutila, Olli Kaijala, Salla Lehto, Tero Vahlberg, Liisa Nissinen, Veli-Matti Kähäri, Pilvi Riihilä
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
